HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
-
BUSINESS Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
-
BUSINESS UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
-
BUSINESS GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
-
REGULATORY 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
-
BUSINESS Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
-
ORGANIZATION Pharma Industry Prepares List of 68 Lawmakers to Support in Likely Snap Poll
September 12, 2024
-
REGULATORY Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
-
REGULATORY AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
-
COMMENTARY LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
-
BUSINESS Mitsubishi Chemical Denies Media Report on Pharma Divestiture
September 9, 2024
-
REGULATORY MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
-
REGULATORY MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
-
REGULATORY Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
September 5, 2024
-
BUSINESS Kidswell Is Open to M&As Amid Challenging Financing Environment: CEO
September 4, 2024
-
BUSINESS BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
September 3, 2024
-
BUSINESS Takeda Pushes Back Shipping Date as Trucker Overtime Cap Hits Logistics
September 2, 2024
-
BUSINESS AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
-
REGULATORY MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
-
REGULATORY Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
